Next Article in Journal
White Nail as a Static Physical Finding: Revitalization of Physical Examination
Previous Article in Journal
Granulomatous Mastitis Due to Non-Tuberculous Mycobacteria: A Diagnostic and Therapeutic Dilemma
Open AccessCase Report

Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis

1
Department of Medicine, Pneumology Unit, Cayenne Hospital Center Andrée Rosemon, F-97306 Cayenne, France
2
Department of Pathology and Centre of Biological Resources (CRB Amazonie), Cayenne Hospital Center Andrée Rosemon, F-97306 Cayenne, France
3
Centre of Biological Resources (CRB Amazonie), Cayenne Hospital Center AndréeRosemon, F-97306 Cayenne, France
4
Chest Diseases Department, Strasbourg University Hospital, F-67000 Strasbourg, France
*
Author to whom correspondence should be addressed.
Current address: Department of Medicine, Pulmonology Unit, Cayenne Hospital Center, Avenue des Flamboyants BP 6006, F-97306 Cayenne, France.
Clin. Pract. 2021, 11(2), 235-240; https://doi.org/10.3390/clinpract11020035
Received: 12 December 2020 / Revised: 6 February 2021 / Accepted: 22 February 2021 / Published: 22 April 2021
Anti-MDA5 antibodies-associated amyopathic dermatomyositisis a rare autoimmune disease that involve polyarthritis, cutaneous and pulmonary manifestations. The development of rapidly progressing interstitial lung disease is a life-threatening complication. We report the case of a 45-year-old woman without medical history, who was addressed to the Pulmonary Department for a polyarthritis with dry cough and hypoxemic dyspnea. Initially there was neither cutaneous manifestation nor interstitial lung disease on chest CT scan. After a few days, the patient developed fatal acute respiratory failure with diffuse ground glass opacities. Identification of anti-MDA5 antibodies allowed establishing diagnosis, despite the fact that the first immunological assessment was negative. Corticosteroid bolus of 1 g for three days and immunosuppressive treatment by cyclophosphamide was only initiated at the acute respiratory distress syndrome stage. Given the rapidly unfavorable prognosis of this entity of amyopathic dermatomyositis, the testing for anti-MDA5 antibodies should be recommended in case of progressive pulmonary symptoms associated with joint signs in order to identify this disease at an early stage and to begin rapid and adequate management. View Full-Text
Keywords: anti-MDA5 antibodies; dermatomyositis; rapidly progressive interstitial pneumopathy; polyarthritis anti-MDA5 antibodies; dermatomyositis; rapidly progressive interstitial pneumopathy; polyarthritis
Show Figures

Figure 1

MDPI and ACS Style

Aissaoui, H.; Alsibai, K.D.; Khayath, N. Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis. Clin. Pract. 2021, 11, 235-240. https://doi.org/10.3390/clinpract11020035

AMA Style

Aissaoui H, Alsibai KD, Khayath N. Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis. Clinics and Practice. 2021; 11(2):235-240. https://doi.org/10.3390/clinpract11020035

Chicago/Turabian Style

Aissaoui, Houari; Alsibai, Kinan D.; Khayath, Naji. 2021. "Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis" Clin. Pract. 11, no. 2: 235-240. https://doi.org/10.3390/clinpract11020035

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop